13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

BIO-TECHNE CORP TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
  • This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
  • The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays.
  • The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 4 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 74.84 FCF 3.31% Buyback 2.32%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Durable Capital Partners Henry Ellenbogen 2.4% $232.9M 2026-03-31
Sequoia Fund 2.9% $177.3M 2026-03-31
Weitz Investment Management Wallace Weitz 2.4% $34.1M 2026-03-31
Glenview Capital Management Larry Robbins 0.2% $9.7M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 3 Last 3 13F filing periods
Net reducers 2 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $411.9M Estimated from net added shares
Reduction amount $124.5M Estimated from net reduced shares
Net share change / base shares +146.7% +5,499,257 / 3,749,714
Baron Capital Ron Baron 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor reduction Shares -10.7% 13F value change -$4.9M
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -51.6% 13F value change -$67.9M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -53.5% 13F value change -$41.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 2,795,147 Last 3 periods -2,233,706 (-79.9%) Total shares 561,441 Value $29.3M
Sequoia Fund 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 866.9% 13F value change +$74.1M
13F 2025-12-31 Filed 2026-02-13
Minor reduction Shares -0.5% 13F value change +$4.2M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 131.4% 13F value change +$91.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 152,417 Last 3 periods +3,239,584 (+2125.5%) Total shares 3,392,001 Value $177.3M
Durable Capital Partners Henry Ellenbogen 3 filing periods
13F 2025-09-30 Filed 2025-11-14
New Shares - 13F value change +$77.7M
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 49.6% 13F value change +$45.2M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 113.3% 13F value change +$110.0M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 3 periods +4,456,017 (New) Total shares 4,456,017 Value $232.9M
Glenview Capital Management Larry Robbins 3 filing periods
13F 2025-09-30 Filed 2025-11-14
New Shares - 13F value change +$20.8M
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 65.7% 13F value change +$15.7M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -69.9% 13F value change -$26.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 3 periods +186,312 (New) Total shares 186,312 Value $9.7M
Weitz Investment Management Wallace Weitz 3 filing periods
13F 2025-09-30 Filed 2025-11-10
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-12
Minor increase Shares 0.1% 13F value change +$2.6M
13F 2026-03-31 Filed 2026-05-14
Major reduction Shares -18.6% 13F value change -$13.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 802,150 Last 3 periods -148,950 (-18.6%) Total shares 653,200 Value $34.1M

Recent mentions

No public mentions.